Flagship Pioneering Special Opportunities Fund II General Partner LLC's Net Worth
$13.7 Million
Who is Flagship Pioneering Special Opportunities Fund II General Partner LLC?
Flagship Pioneering Special Opportunities Fund II General Partner LLC has an estimated net worth of $13.7 Million. This is based on reported shares across multiple companies, which include Omega Therapeutics, Inc., Foghorn Therapeutics Inc., and Sigilon Therapeutics, Inc..
SEC CIK
Flagship Pioneering Special Opportunities Fund II General Partner LLC's CIK is 0001826217
Past Insider Trading and Trends
2020 was Flagship Pioneering Special Opportunities Fund II General Partner LLC's most active year for acquiring shares with 10 total transactions. Flagship Pioneering Special Opportunities Fund II General Partner LLC's most active month to acquire stocks was the month of July. 2021 was Flagship Pioneering Special Opportunities Fund II General Partner LLC's most active year for disposing of shares, totalling 11 transactions. Flagship Pioneering Special Opportunities Fund II General Partner LLC's most active month to dispose stocks was the month of July. 2023 saw Flagship Pioneering Special Opportunities Fund II General Partner LLC paying a total of $19,208,731.80 for 3,323,310 shares, this is the most they've acquired in one year. In 2023 Flagship Pioneering Special Opportunities Fund II General Partner LLC cashed out on 797,720 shares for a total of $11,901,982.40, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Omega Therapeutics, Inc. (OMGA) Snapshot price: $3.585
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| +60.26% | 3.32M |
$5.78 | $19,208,731.80 | 8.84M |
Feb 27
| |||
Form 4
|
∞
| 23.71M |
$17.00 |
—
| 23.71M |
Aug 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Foghorn Therapeutics Inc. (FHTX) Snapshot price: $3.19
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 22
| |||
Form 4
|
∞
| 12.67M |
$16.00 |
—
| 12.67M |
Oct 27
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |
Sigilon Therapeutics, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -797.72K |
$14.92 | -$11,901,982.40 |
0
|
Aug 11
| |||
Form 4
|
∞
| 10.37M |
—
|
—
| 10.37M |
Dec 8
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
No matching records found |